Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Cytokinetics, Incorporated

Cytokinetics, Incorporated (CYTK) Stock Overview

Explore Cytokinetics, Incorporated’s financial performance, market position, analyst ratings, and future outlook.

CYTK●NASDAQ
HealthcareBiotechnology
$76.84
$0.34(0.44%)
U.S. Market opens in 64h 56m

Cytokinetics, Incorporated (CYTK)

Meyka AI Score

Z

Key Financials

Market Cap9.6B
P/E Ratio-10.75
EPS (TTM)$-7.22
ROE1.64%
Fundamental Analysis

AI Price Forecasts

1 Month$92.40
3 Months$108.59
1 Year Target$74.59

CYTK Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Cytokinetics, Incorporated (NASDAQ: CYTK) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Cytokinetics, Incorporated's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of CYTK on the NASDAQ shows an RSI of 47.34, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $74.59 for the NASDAQ listing.

Key metrics behind Cytokinetics, Incorporated's NASDAQ-traded stock include a P/E ratio of -10.75 and a market capitalization of 9.6B. Combined with our AI analysis, these give both institutional and retail investors a clear view of CYTK on the NASDAQ.

Price Performance (NASDAQ: CYTK)

1-Day Change
-0.44%
5-Day Change
5.69%
1-Month Change
-5.26%
3-Month Change
-1.56%
6-Month Change
13.10%
Year-to-Date (YTD) Change
20.93%
1-Year Change
101.94%
3-Year Change
133.27%
5-Year Change
144.79%
All-Time (Max) Change
-20.46%

Contact Information

https://www.cytokinetics.com
650 624 3000
350 Oyster Point Boulevard, South San Francisco, CA, 94080

Company Facts

6,730 Employees
IPO DateApr 26, 2004
CountryUS
Actively Trading

Frequently Asked Questions